.Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA08_Bevacizumab.Bevacizumab .Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA08_Bevacizumab.Bevacizumab| name: | Bevacizumab |
| ATC code: | S01LA08 | route: | intravenous |
| n-compartments | 2 |
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is mainly used as an anti-angiogenic agent in the treatment of various cancers and is also approved for ophthalmic use such as neovascular age-related macular degeneration. It is widely approved and used today.
Population pharmacokinetic parameters reported for typical adult patients receiving intravenous bevacizumab; primarily in oncology treatment and ophthalmology (off-label/compounded for intraocular use).
Han, K, et al., & Jin, J (2016). Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer chemotherapy and pharmacology 78(2) 341–351. DOI:10.1007/s00280-016-3079-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27329360
Rietveld, PCS, et al., & Koolen, SLW (2024). Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 176 116820–None. DOI:10.1016/j.biopha.2024.116820 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38810398
Li, CSW, et al., & Cronenberger, C (2020). Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin. Cancer chemotherapy and pharmacology 85(3) 487–499. DOI:10.1007/s00280-019-03946-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31768697